Robotic Brachytherapy and Sublobar Resection for T1 Non-Small Cell Lung Cancer in High-Risk Patients

被引:6
|
作者
Blasberg, Justin D. [1 ]
Belsley, Scott J.
Schwartz, Gary S.
Evans, Andrew
Wernick, Iddo
Ashton, Robert C., Jr.
Bhora, Faiz Y.
Connery, Cliff P.
机构
[1] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Dept Surg, New York, NY 10023 USA
来源
ANNALS OF THORACIC SURGERY | 2010年 / 89卷 / 02期
关键词
THORACOSCOPIC WEDGE RESECTION; LIMITED RESECTION; I-125; BRACHYTHERAPY; LOBECTOMY; SEGMENTECTOMY; CARCINOMA; PULMONARY; SURVIVAL; IMPLANTATION;
D O I
10.1016/j.athoracsur.2009.09.052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Sublobar lung resection and brachytherapy seed placement is gaining acceptance for T1 non-small cell lung cancer (NSCLC) in select patients with comorbidities precluding lobectomy. Our institution first reported utilization of the da Vinci system for robotic brachytherapy developed experimentally in swine and applied to high-risk patients 5 years ago. We now report seed dosimetrics and midterm follow-up. Methods. Eleven high-risk patients with stage IA NSCLC who were not candidates for conventional lobectomy underwent limited resection of 12 primary tumors. To reduce locoregional recurrence, I-125 brachytherapy seeds were robotically sutured intracorporeally over resection margins to deliver 14,400 cGy 1 cm from the implant plane. Patients were followed with dosimetric computed tomography scans at 30 +/- 16 days. Survival and sites of recurrence were documented. Results. Resected tumor size averaged 1.48 +/- 0.38 cm (range, 1.1 to 2.1 cm). Perioperative mortality was 0% and recurrence was 9% (1 of 11 [margin recurrence at 6 months with resultant mortality at 1 year]). Follow-up duration was 31.82 +/- 17.35 months. Dosimetrics confirmed 14,400 cGy delivery using 24.21 +/- 4.6 I-125 seeds (range, 17 to 30 seeds) over a planning target volume of 10.29 +/- 2.39 cc(3). Overall, 84.1% of the planning target volume was covered by 100% of the prescription dose (V100), and 88.2% was covered by 87% of the prescription dose (V87), comparable to open dosimetric data at our institution. Follow-up imaging confirmed seed stability in all patients. Conclusions. Robotic I-125 brachytherapy seed placement is a feasible adjuvant procedure to reduce the incidence of recurrence after sublobar resection in medically compromised patients. Tailored robotic seed placement delivers an exact dosing regimen in a minimally invasive fashion with equivalent precision to open surgery. (Ann Thorac Surg 2010;89:360-7) (C) 2010 by The Society of Thoracic Surgeons
引用
收藏
页码:360 / 367
页数:8
相关论文
共 50 条
  • [1] The Role of Completion Lobectomy Following Sublobar Resection in Patients with T1 Non-Small Cell Lung Cancer
    Turna, A.
    Ozcibik, G.
    Sarbay, I.
    Ersen, E.
    Kaynak, K.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S214 - S214
  • [2] Sublobar Resection and Robotic Interstitial Brachytherapy for Early-Stage Non-small Cell Lung Cancer
    Evans, A. J.
    Connery, C.
    Bhora, F.
    Choi, W.
    Lee, D.
    Jain, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S558 - S558
  • [3] Is Sublobar Resection Feasible for High-Risk Pathologic Stage I Non-small Cell Lung Cancer?
    Akamine, Takaki
    Wakasu, Sho
    Matsubara, Taichi
    Yamaguchi, Masafumi
    Yamazaki, Koji
    Hamatake, Motoharu
    Kometani, Takuro
    Kinoshita, Fumihiko
    Kohno, Mikihiro
    Shimokawa, Mototsugu
    Takenaka, Tomoyoshi
    Yoshizumi, Tomoharu
    ANNALS OF SURGICAL ONCOLOGY, 2024, : 4161 - 4172
  • [4] Comparison between sublobar resection and 125iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer
    Santos, R
    Colonias, A
    Parda, D
    Trombetta, M
    Maley, RH
    Macherey, R
    Bartley, S
    Santucci, T
    Keenan, RJ
    Landreneau, RJ
    SURGERY, 2003, 134 (04) : 691 - 697
  • [5] Sublobar Resection and Robotic Interstitial Brachytherapy for Early Stage Non Small Cell Lung Cancer
    Evans, A. J.
    Connery, C.
    Bhora, F.
    Choi, W.
    Lee, D.
    Jain, A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S293 - S293
  • [6] Sublobar Resection with Brachytherapy Mesh for Stage I Non-Small Cell Lung Cancer
    Odell, David D.
    Kent, Michael S.
    Fernando, Hiran C.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2010, 22 (01) : 32 - 37
  • [7] Comparison between sublobar resection and 125iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer -: Discussion
    Michelassi, F
    Rodriguez, JL
    Rikkers, LF
    SURGERY, 2003, 134 (04) : 697 - 697
  • [8] Robotic Surgery for Non-Small Cell Lung Cancer Treatment in High-Risk Patients
    Zirafa, Carmelina Cristina
    Romano, Gaetano
    Sicolo, Elisa
    Cariello, Claudia
    Morganti, Riccardo
    Conoscenti, Lucia
    Hung-Key, Teresa
    Davini, Federico
    Melfi, Franca
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [9] Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer
    Fernando, HC
    Santos, RS
    Benfield, JR
    Grannis, FW
    Keenan, RJ
    Luketich, JD
    Close, JM
    Landreneau, RJ
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 129 (02): : 261 - 267
  • [10] Intraoperative I-125 vicryl mesh brachytherapy after sublobar resection for high-risk stage I non-small cell lung cancer
    Voynov, GH
    Heron, DE
    Lin, CJ
    Chen, A
    Quinn, A
    Santos, R
    Colonias, A
    Landreneau, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S240 - S241